{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:59:22Z","timestamp":1780084762402,"version":"3.54.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10384-020-00770-z","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T07:03:28Z","timestamp":1600239808000},"page":"628-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis"],"prefix":"10.1007","volume":"64","author":[{"given":"Yoshihiko","family":"Isshiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305:97\u2013102.","journal-title":"J Neurol Sci"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","volume":"11","author":"A Evoli","year":"2001","unstructured":"Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord. 2001;11:208\u201316.","journal-title":"Neuromuscul Disord"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, Ruckert JC. Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol. 2018;265:2773\u2013822.","journal-title":"J Neurol"},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/ICU.0b013e328310da18","volume":"19","author":"AA Antonio-Santos","year":"2008","unstructured":"Antonio-Santos AA, Eggenberger ER. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol. 2008;19:468\u201378.","journal-title":"Curr Opin Ophthalmol"},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0140-6736(86)92259-2","volume":"1","author":"S Mossman","year":"1986","unstructured":"Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet. 1986;1:116\u20139.","journal-title":"Lancet"},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"DB Drachman","year":"1994","unstructured":"Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797\u2013810.","journal-title":"N Engl J Med"},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00019052-200110000-00006","volume":"14","author":"J Palace","year":"2001","unstructured":"Palace J, Vincent A, Beeson D. Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol. 2001;14:583\u20139.","journal-title":"Curr Opin Neurol"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365\u20138.","journal-title":"Nat Med"},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1055\/s-0039-1700527","volume":"39","author":"M O'Hare","year":"2019","unstructured":"O'Hare M, Doughty C. Update on ocular myasthenia gravis. Semin Neurol. 2019;39:749\u201360.","journal-title":"Semin Neurol"},{"key":"770_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","volume":"13","author":"MK Mittal","year":"2011","unstructured":"Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis. 2011;13:46\u201352.","journal-title":"J Clin Neuromuscul Dis"},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","volume":"209","author":"S Apinyawasisuk","year":"2020","unstructured":"Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S. Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol. 2020;209:10\u20137.","journal-title":"Am J Ophthalmol"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16\u201323.","journal-title":"Neurology."},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve. 2008;38:1553\u2013622.","journal-title":"Muscle Nerve"},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/01.cnd.0000155026.66153.f0","volume":"6","author":"HD Katzberg","year":"2005","unstructured":"Katzberg HD, Bril V. A comparison of electrodiagnostic tests in ocular myasthenia gravis. J Clin Neuromuscul Dis. 2005;6:109\u201313.","journal-title":"J Clin Neuromuscul Dis"},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105.","journal-title":"Am J Ophthalmol"},{"key":"770_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fneur.2019.00829","volume":"10","author":"I Ayzenberg","year":"2019","unstructured":"Ayzenberg I, Ellrichmann G, Schroeder C, Tonges L, Klasing A, Pappa V, et al. Brainstem encephalitis with low-titer acetylcholine receptor antibodies mimicking myasthenia gravis. Front Neurol. 2019;10:829.","journal-title":"Front Neurol"},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/01676830.2017.1423350","volume":"37","author":"R Rajput","year":"2018","unstructured":"Rajput R, Sachdev A, Din N, Damato EM, Murray A. False positive acetylcholine receptor antibodies in a case of unilateral chronic progressive external ophthalmoplegia: case report and review of literature. Orbit. 2018;37:385\u20138.","journal-title":"Orbit"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2169\/internalmedicine.55.6262","volume":"55","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Satomi K. Overlap of myasthenia gravis and Miller Fisher syndrome. Intern Med. 2016;55:1917\u20138.","journal-title":"Intern Med"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1212\/01.WNL.0000041625.41937.FF","volume":"59","author":"CP Plested","year":"2002","unstructured":"Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology. 2002;59:1682\u20138.","journal-title":"Neurology"},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015;72:1170\u20134.","journal-title":"JAMA Neurol"},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve. 2018;57:756\u201360.","journal-title":"Muscle Nerve"},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018;128:15\u201324.","journal-title":"Int J Neurosci"},{"key":"770_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM. Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol. 2018;79:113\u20137.","journal-title":"Eur Neurol"},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054\u20139.","journal-title":"Neurology"},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243\u20138.","journal-title":"Arch Neurol"},{"key":"770_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314\u201320.","journal-title":"J Neurol"},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0161-6420(99)00138-4","volume":"107","author":"P Mullaney","year":"2000","unstructured":"Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107:504\u201310.","journal-title":"Ophthalmology"},{"key":"770_CR28","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89:1330\u20134.","journal-title":"Br J Ophthalmol"},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","volume":"402","author":"Y Ozawa","year":"2019","unstructured":"Ozawa Y, Uzawa A, Kanai T, Oda F, Yasuda M, Kawaguchi N, et al. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. J Neurol Sci. 2019;402:12\u20135.","journal-title":"J Neurol Sci"},{"key":"770_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","volume":"68","author":"A Komiyama","year":"2000","unstructured":"Komiyama A, Arai H, Kijima M, Hirayama K. Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2000;68:214\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70:327\u201334.","journal-title":"Ann Thorac Surg."},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/14737175.9.3.351","volume":"9","author":"NE Gilhus","year":"2009","unstructured":"Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother. 2009;9:351\u20138.","journal-title":"Expert Rev Neurother"},{"key":"770_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43:428\u201335.","journal-title":"Autoimmunity"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141\u20139.","journal-title":"Muscle Nerve"},{"key":"770_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46:166\u201373.","journal-title":"Muscle Nerve"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4103\/aian.AIAN_97_17","volume":"20","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Yang C, Zhang L, Yi Q, Hao Z. Efficacy and safety of tacrolimus in myasthenia gravis: a systematic review and meta-analysis. Ann Indian Acad Neurol. 2017;20:341\u20137.","journal-title":"Ann Indian Acad Neurol"},{"key":"770_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/ene.14039","volume":"27","author":"Y Nishida","year":"2020","unstructured":"Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, et al. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis. Euro J Neurol. 2020;27:100\u20134.","journal-title":"Euro J Neurol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-020-00770-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T23:33:12Z","timestamp":1631748792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-020-00770-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s10384-020-00770-z","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Isshiki, None; O. Mimura, Lecture fee (Santen, Senju, Otsuka, Pfizer, Alcon, GSK); F. Gomi, Grant, Lecture fee (Pfizer, Novartis, Santen, Senju), Grant (Alcon), Lecture fee (Bayer).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}